Home » Stocks » HRTX

Heron Therapeutics, Inc. (HRTX)

Stock Price: $17.78 USD 0.63 (3.67%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $17.65 -0.13 (-0.73%) Apr 20, 7:00 PM
Market Cap 1.63B
Revenue (ttm) 88.64M
Net Income (ttm) -227.28M
Shares Out 90.77M
EPS (ttm) -2.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $17.78
Previous Close $17.15
Change ($) 0.63
Change (%) 3.67%
Day's Open 17.00
Day's Range 16.97 - 17.91
Day's Volume 1,012,662
52-Week Range 12.52 - 22.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

1 week ago - Zacks Investment Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0.00% and 12.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

SAN DIEGO, Jan. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

3 months ago - PRNewsWire

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

SAN DIEGO, Nov. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

5 months ago - PRNewsWire

This biotech titan should be a top player on the merger and acquisition scene next year.

Other stocks mentioned: BIIB, AUPH, SAVA
5 months ago - The Motley Fool

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

Other stocks mentioned: CBPO, GLPG, ILMN, IONS, RGNX, LGND
5 months ago - InvestorPlace

Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.

6 months ago - Zacks Investment Research

SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatme...

6 months ago - PRNewsWire

SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.

7 months ago - PRNewsWire

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.

7 months ago - PRNewsWire

Bargain hunters pounced on this beaten-down biotech stock last month. Here's why.

8 months ago - The Motley Fool

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -3.39% and 38.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

SAN DIEGO, Aug. 5, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.

8 months ago - PRNewsWire

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.

9 months ago - Zacks Investment Research

Its non-opioid painkiller gets a rejection over non-clinical issues.

9 months ago - The Motley Fool

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatmen...

9 months ago - PRNewsWire

Heron Therapeutics and Novavax are two key healthcare stocks to watch this month.

Other stocks mentioned: NVAX
10 months ago - The Motley Fool

Heron Therapeutics (NASDAQ: HRTX) shares are trading higher on Wednesday after Guggenheim initiated coverage on the company's stock with a Buy rating and $24 price target.

10 months ago - Benzinga

AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.

Other stocks mentioned: ABBV, ADVM
11 months ago - The Motley Fool

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 9.52% and 25.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Heron Therapeutics and Intercept Pharmaceuticals are too cheap to ignore right now.

Other stocks mentioned: ICPT
1 year ago - The Motley Fool

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -12.07% and 0.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Heron Therapeutics: Looking For Entry Following HTX-011 PDUFA Extension

1 year ago - Seeking Alpha

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Heron Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

1 year ago - Zacks Investment Research

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

Other stocks mentioned: AKCA, AMAG, AXSM, CRON, EIDX, LGND, PRTK ...
1 year ago - Benzinga

As of late, it has definitely been a great time to be an investor in Heron Therapeutics, Inc. (HRTX).

1 year ago - Zacks Investment Research

Heron Therapeutics: Looking Solid Heading Into 2020

1 year ago - Seeking Alpha

Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 30.00% and 25.64%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

These two biotech stocks are poised for big gains next year.

Other stocks mentioned: AMRN
1 year ago - The Motley Fool

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

Other stocks mentioned: FDX, IMMU, KALV, VBIV
1 year ago - InvestorPlace

A high-risk transformative move sent one of these stocks lower.

Other stocks mentioned: AVT, HPQ
1 year ago - The Motley Fool

The steep sell-off in biotech over the past two weeks has obscured some positive developments around Heron Therapeutics.

1 year ago - Seeking Alpha

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

You should never blindly follow the crowd, but it pays to watch what the biggest and brightest on Wall Street are doing.

Other stocks mentioned: AMZN, WPM
1 year ago - The Motley Fool

Despite better than expected Q2 results, the stock of small biopharma Heron Therapeutics sits near 52-week lows.

1 year ago - Seeking Alpha

The biotechnology industry is an exciting one. A mix of technology and a better understanding of the human body has led to several very exciting breakthroughs over the past several years, and we’re seei...

Other stocks mentioned: AMRN
1 year ago - GuruFocus

These three biotech stocks might be outstanding buys right now.

Other stocks mentioned: CELG, IOVA
1 year ago - The Motley Fool

Amarin and Heron Therapeutics could turn out to be outstanding bargains.

Other stocks mentioned: AMRN
1 year ago - The Motley Fool

Not all CRLs are created equal. Investors likely overreacted to the recent announcement of Heron’s Complete Response Letter.

1 year ago - Seeking Alpha

These stocks are bargains.

Other stocks mentioned: CVS, ILMN
1 year ago - The Motley Fool

About HRTX

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycli... [Read more...]

Industry
Biotechnology
IPO Date
Aug 26, 1987
CEO
Barry Quart
Employees
223
Stock Exchange
NASDAQ
Ticker Symbol
HRTX
Full Company Profile

Financial Performance

In 2020, HRTX's revenue was $88.64 million, a decrease of -39.28% compared to the previous year's $145.97 million. Losses were -$227.28 million, 11.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is 34.00, which is an increase of 91.23% from the latest price.

Price Target
$34.00
(91.23% upside)
Analyst Consensus: Strong Buy